29 Cord-Blood Transplantation in Patients with Minimal Residual Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602074
28 Noninvasive low-level laser therapy for thrombocytopenia.
http://stm.sciencemag.org/content/8/349/349ra101.abstract
27 Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
http://www.nejm.org/doi/full/10.1056/NEJMoa1505533
26 Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01041-7/abstract
25 The structure of a key red blood cell membrane protein provides a basis for understanding mutations that lead to red blood cell diseases.
http://www.sciencemag.org/content/350/6261/680.abstract
24 PCSK6-mediated corin activation is essential for normal blood pressure.
http://www.nature.com/nm/journal/v21/n9/abs/nm.3920.html
23 Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1503479
22 Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
http://www.nejm.org/doi/full/10.1056/NEJMoa1501035
21 Idarucizumab for Dabigatran Reversal.
http://www.nejm.org/doi/full/10.1056/NEJMoa1502000
20 Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61999-1/abstract
19 Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61495-1/fulltext
18 Age of Transfused Blood in Critically Ill Adults.
http://www.nejm.org/doi/full/10.1056/NEJMoa1500704
17 An early stage in mouse blood development is reconstructed from gene expression data on thousands of single cells.
http://www.nature.com/nbt/journal/v33/n3/abs/nbt.3154.html
16 A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis.
http://stm.sciencemag.org/content/7/277/277ra29
15 Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis.
http://www.nejm.org/doi/full/10.1056/NEJMoa1405760
14 Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera.
http://www.nejm.org/doi/full/10.1056/NEJMoa1409002
13 Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera.
http://www.nejm.org/doi/full/10.1056/NEJMoa1409002
12 Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome.
http://www.nejm.org/doi/full/10.1056/NEJMoa1312890
11 Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B.
http://www.nejm.org/doi/full/10.1056/NEJMoa1305074
10 Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms.
http://www.nejm.org/doi/full/10.1056/NEJMoa1311347
|
